FDA Approves Brixadi Injection as Opioid Use Disorder Treatment

The US Food and Drug Administration has approved Brixadi extended-release injection for under the skin use as a treatment for moderate to severe opioid use disorder, according to the FDA Tuesday.

Brixadi can be administered through a weekly injection for patients who have started treatment with a single dose of a transmucosal buprenorphine drug or who are already being treated buprenorphine, the FDA said.

It can also be administered through a monthly version for patients already treated with buprenorphine, according to the agency.

This story was produced by Bloomberg Law Automation.